The company in question is, Alkermes plc (NASDAQ:ALKS) currently with a stock price of 42.75 (-2.55% today). The market cap for Alkermes plc is 6637.57, and is in the sector Healthcare, and Drug Delivery industry. The target price for Alkermes plc is 52.82. Currently Alkermes plc is trading with a P/E of *TBA, and a forward P/E of 134.16. Average volume for Alkermes plc is 774.88 and so far today it is 527954.
Performance in the last year for Alkermes plc has been -26.00%. For EPS growth, Alkermes plc has seen a growth of -635.70%, and is looking to grow in the next year to 375.00%. More long term stats show that EPS growth has been -26.20% over the last five years and could be *TBA for the next five years. Alkermes plc has seen sales growth quarter over quarter at 28.90%, with EPS growth quarter over quarter at -0.70%. The 20-day simple moving average is -8.51%, with the 200-day simple moving average coming to -1.27%.
Since the IPO date for Alkermes plc on the 7/16/1991, Alkermes plc has seen performance year to date to be -44.73%. With Alkermes plc trading at 42.75, the dividend yield is *TBA, and the EPS is -1.83.
So could Alkermes plc, be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 9.94 and the P/B is at 5.34. The P/cash is 10.12, with P/free cash flow at *TBA.
Alkermes plc ability to deal with debt shows that the current ratio is 3.9, and the quick ratio is 3.7. This is with long term debt/equity at 0.23, and total debt/equity at 0.28.
In terms of margins, Alkermes plc has a gross margin of 80.50%, an operating margin of -40.20% and a profit margin of -41.20%.Payout ratio for Alkermes plc is *TBA. Return on assets come to -15.00% with return on investment coming to -13.70%.
Insider ownership for Alkermes plc, is at 0.70% and institutional ownership comes to 97.90%. Outstanding shares are at 151.3. While shares float is 150.3. The float short is currently 3.45%, and short ratio is 6.69.